Table of Contents
- What Is Cortisol-Binding Globulin?
- Free Cortisol vs Bound Cortisol: Understanding the Difference
- How CBG and Cortisol Work Together in the Bloodstream
- Cortisol Transport Protein Research: A Historical and Modern Overview
- Free Cortisol Bioavailability and Why It Matters
- Cortisol Binding Globulin and Estrogen: Key Hormonal Connections
- CBG and Stress: What Happens During Acute and Chronic Stress
- Cortisol's Biologically Active Form: Why Only Free Cortisol Acts
- Cortisol CBG Research: Landmark Studies and 2025 Updates
- Free Cortisol, the HPA Axis, and Clinical Implications
- CBG Gene Mutations and What They Reveal
- When Should Clinicians Measure CBG?
- Frequently Asked Questions
- Conclusion
Introduction
When most people hear the word "cortisol," they think of the body's primary stress hormone — a molecule released during difficult moments, responsible for everything from raising blood sugar to suppressing inflammation. What fewer people appreciate, however, is that the vast majority of cortisol traveling through the bloodstream at any given moment is not actually doing anything at all.
It is bound, carried, and essentially silenced by a remarkable transport protein called cortisol-binding globulin (CBG).
Understanding cortisol and cortisol binding globulin research is not merely an academic exercise. It sits at the heart of how we interpret cortisol lab tests, how we understand stress physiology, and how disorders ranging from pregnancy complications to adrenal insufficiency to chronic fatigue are diagnosed and managed. Yet despite its clinical importance, CBG remains one of the most underappreciated molecules in endocrinology.
This comprehensive guide brings together decades of foundational science alongside the most current cortisol CBG research, including a landmark 2025 review published in Frontiers in Endocrinology, to give readers — whether patients, clinicians, or curious minds — a complete picture of cortisol transport proteins and why they matter.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance Drops
What Is Cortisol-Binding Globulin?
Cortisol-binding globulin, commonly abbreviated as CBG and sometimes referred to by its older name transcortin, is a plasma glycoprotein that serves as the primary transport protein for cortisol in human blood. It belongs to a large and diverse superfamily of proteins known as serine protease inhibitors, or SERPINs, and is specifically classified as SERPINA6 in modern molecular nomenclature.
A 2025 review published in Frontiers in Endocrinology, titled "Binding for life: corticosteroid binding globulin from vertebrate…", confirms that CBG was first discovered in the 1950s and has since become recognized as one of the most biologically important transport proteins in vertebrate endocrinology. The protein is not a passive carrier. It actively governs how much cortisol is available to tissues at any moment, functioning as a dynamic hormonal buffer.
Key structural and functional facts about CBG:
- It is a glycoprotein with a molecular weight of approximately 52–58 kilodaltons
- It belongs to the SERPIN family (specifically SERPINA6), sharing structural features with proteins like alpha-1 antitrypsin
- It has a single high-affinity binding site for cortisol
- It is primarily produced by the liver, though there is some evidence of localized production in other tissues
- It binds cortisol with high specificity, though it also has affinity for other corticosteroids including progesterone and corticosterone
What makes CBG biologically fascinating is the fact that its binding affinity for cortisol is temperature-sensitive. At physiological core body temperature (~37°C), CBG binds cortisol tightly. However, at sites of inflammation — where tissue temperature rises — CBG's binding affinity decreases, potentially releasing more free cortisol precisely where an immune response is occurring. This suggests CBG plays an active, targeted role in directing cortisol to sites of need, rather than simply acting as a passive reservoir.
The protein's discovery in the 1950s opened an entirely new chapter in understanding steroid hormone transport, laying the groundwork for the rich field of cortisol transport protein research we continue to explore today.
Free Cortisol vs Bound Cortisol: Understanding the Difference
One of the most clinically important distinctions in cortisol physiology is the difference between free cortisol vs bound cortisol. These are not simply two compartments of the same molecule — they represent fundamentally different biological states with entirely different implications for how the body functions.
The Distribution of Cortisol in Blood
When cortisol is secreted by the adrenal glands and enters the circulation, it does not float freely in the plasma as a lone molecule. Instead, it is rapidly taken up by binding proteins. Approximately 80–90% of circulating cortisol is bound to corticosteroid-binding globulin (CBG), leaving only a small free fraction that is biologically active. An additional 5–10% binds loosely to albumin, while the remaining 5–10% circulates as free, unbound cortisol.
This distribution has enormous clinical consequences. When a standard laboratory test measures total cortisol in the blood, it is measuring the sum of all three fractions — CBG-bound, albumin-bound, and free. But only the free fraction can cross cell membranes, bind to glucocorticoid receptors, and trigger a biological response.
Why the Distinction Matters Clinically
Consider a patient whose liver is producing less CBG due to cirrhosis. Their total cortisol reading might appear lower than normal, yet they could have a perfectly adequate or even elevated free cortisol level. Conversely, a pregnant woman whose CBG levels are dramatically elevated by rising estrogen will show high total cortisol on a standard blood test — but her free cortisol may be within normal range.
In both cases, interpreting total cortisol without accounting for CBG levels can lead to diagnostic errors. This is precisely why the field of cortisol CBG research has devoted so much attention to developing reliable methods for assessing free cortisol independently.
How Free Cortisol Is Measured
Free cortisol can be estimated through several methods:
- Salivary cortisol — Saliva contains predominantly free cortisol because CBG is largely excluded from salivary secretion, making it a widely used surrogate
- Urinary free cortisol (UFC) — The kidneys filter free cortisol into urine, providing a 24-hour integrated measure
- Equilibrium dialysis — Considered the gold standard for directly measuring free plasma cortisol, though technically demanding
- The Free Cortisol Index (FCI) — A calculated ratio of total cortisol to CBG, discussed in detail in a later section
The key takeaway is this: understanding free cortisol vs bound cortisol is not optional for anyone interpreting cortisol data in clinical practice. The binding proteins — above all, CBG — are the gatekeepers of cortisol bioactivity.
How CBG and Cortisol Work Together in the Bloodstream
The relationship between CBG and cortisol is one of dynamic equilibrium. These two molecules exist in a constant state of association and dissociation, governed by the laws of binding kinetics, and modulated by an array of physiological variables including temperature, pH, and the presence of inflammatory mediators.
The Buffering Function
Think of CBG as a molecular sponge for cortisol. When the adrenal glands release a pulse of cortisol — as they do each morning in a circadian rhythm-driven surge — CBG captures the majority of that cortisol almost immediately, buffering the free fraction and preventing it from flooding tissues all at once. Between pulses, CBG slowly releases cortisol back into the free fraction, maintaining a relatively stable reservoir of available hormone.
This buffering function is critically important for preventing excessive glucocorticoid exposure to sensitive tissues. A 2025 review in Frontiers in Endocrinology explicitly reinforces that glucocorticoids are normally bound to CBG to limit tissue exposure, underscoring the protein's role in hormone buffering and protection against cortisol toxicity.
Neutrophil Elastase: The Release Mechanism
One of the more remarkable mechanisms in CBG biology involves neutrophil elastase, an enzyme released by activated neutrophils during inflammation. When neutrophil elastase cleaves a reactive center loop on the CBG molecule, the protein undergoes a conformational change that dramatically reduces its binding affinity for cortisol. The result: cortisol is released locally at sites of immune activation.
This mechanism elegantly explains why the immune system appears to have a built-in mechanism for accessing cortisol on demand — and why CBG is not just a transport vehicle but an active participant in immune-endocrine communication.
Circadian Rhythm and CBG
Cortisol follows a well-characterized circadian rhythm, peaking in the early morning hours and declining throughout the day. CBG concentrations, by contrast, remain relatively stable over the course of a day, though they are subject to longer-term regulation by hormones, liver function, and inflammation. This means that the ratio of free to bound cortisol shifts subtly throughout the day, even as total cortisol fluctuates dramatically.
Understanding this interplay is essential for interpreting cortisol tests ordered at different times of day and for understanding why certain conditions — like adrenal insufficiency or Cushing's syndrome — present differently depending on when samples are collected.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsCortisol Transport Protein Research: A Historical and Modern Overview
The story of cortisol transport protein research spans more than seven decades and represents one of the quieter but most consequential threads in the history of endocrinology. Understanding how this field evolved helps contextualize the significance of current discoveries.
The 1950s: Discovery of CBG
CBG was first identified in the 1950s, when researchers observed that cortisol in plasma was not entirely freely soluble but appeared to be associated with a protein fraction. This was a revolutionary finding at the time, challenging the prevailing view that steroid hormones simply floated through the blood unattached. The protein was initially called transcortin — a name still used in some older literature — before being reclassified as cortisol-binding globulin and later as SERPINA6.
The 2025 Frontiers in Endocrinology review confirms this historical timeline, noting that CBG's discovery in the 1950s marked the beginning of systematic research into steroid hormone transport.
The 1980s–2000s: Molecular Characterization
The molecular biology revolution of the 1980s and 1990s transformed our understanding of CBG. Researchers cloned the CBG gene, identified its SERPIN family classification, and began mapping the structural features that determine its binding affinity for cortisol. The discovery that CBG shared structural homology with serine protease inhibitors — proteins known for their roles in coagulation, inflammation, and tissue remodeling — hinted at functional connections beyond simple hormone transport.
During this period, researchers also began identifying CBG gene mutations in humans, providing rare but invaluable natural experiments into what happens when CBG function is disrupted.
The 2000s: Clinical Utility and the Free Cortisol Index
The study reported that CBG should be measured alongside total cortisol in acutely ill patients to avoid misinterpretation of cortisol status. This recommendation represented a significant clinical advance, highlighting that cortisol transport protein research was not merely theoretical but had direct implications for patient care.
2025: A Comprehensive Modern Review
The most current major contribution to this field is the 2025 Frontiers in Endocrinology review, which synthesizes decades of research on CBG biology, its evolutionary conservation across vertebrates, its SERPINA6 classification, and its multifaceted roles in glucocorticoid regulation. This review signals a renewed scientific interest in CBG at a time when precision medicine demands more nuanced hormone assessment tools than simple total cortisol measurements.
The breadth of modern cortisol transport protein research now encompasses molecular biology, clinical diagnostics, evolutionary biology, inflammation science, and reproductive endocrinology — a testament to how central this single binding protein is to human physiology.
Free Cortisol Bioavailability and Why It Matters
Free cortisol bioavailability is the concept at the functional heart of everything discussed in this article. It refers to the proportion of circulating cortisol that is actually available to enter cells, bind to glucocorticoid receptors, and exert biological effects. Understanding bioavailability is what separates a superficial reading of a cortisol lab value from a genuinely informative clinical assessment.
The Bioavailability Equation
Free cortisol bioavailability is determined by a relatively simple set of variables:
- Total cortisol production by the adrenal glands
- CBG concentration in plasma
- CBG binding affinity, which can be affected by temperature, pH, and genetic variants
- Albumin concentration (relevant for the loosely bound fraction)
- Metabolic clearance rate of free cortisol
When any of these variables shifts, bioavailability changes — even if total cortisol remains constant. This is why a single total cortisol measurement taken in isolation often tells an incomplete story.
Clinical Scenarios Where Bioavailability Is Altered
Pregnancy: During pregnancy, rising estrogen levels dramatically stimulate hepatic CBG production, sometimes doubling or tripling plasma CBG concentrations. Total cortisol rises correspondingly, but free cortisol bioavailability may remain relatively unchanged or increase only modestly. Clinicians who do not account for this can incorrectly suspect hypercortisolism in pregnant women based on elevated total cortisol alone.
Critical illness and sepsis: During severe illness, CBG levels fall sharply — partly due to reduced hepatic synthesis and partly due to increased cleavage by neutrophil elastase at sites of inflammation. The result is paradoxically higher free cortisol bioavailability even when total cortisol may not look dramatically elevated. This has important implications for assessing adrenal function in critically ill patients.
Obesity: Some research has suggested that obese individuals may have altered CBG levels and therefore different free cortisol bioavailability compared to lean individuals, potentially contributing to the metabolic dysregulation associated with obesity.
Liver disease: Since CBG is primarily synthesized in the liver, hepatic cirrhosis or severe liver disease reduces CBG production. This lowers total cortisol measurements but does not necessarily indicate adrenal insufficiency — because free cortisol bioavailability may be maintained or even enhanced.
The Role of the Free Cortisol Index
Because directly measuring free cortisol requires technically demanding methods like equilibrium dialysis, researchers have sought practical clinical alternatives. The Free Cortisol Index (FCI) — calculated as total cortisol divided by CBG concentration — was validated in the 2003 JCEM study mentioned earlier and is now used in some clinical contexts as a surrogate for true free cortisol when direct measurement is unavailable.
The FCI is not perfect. It makes assumptions about binding stoichiometry that may not hold in all clinical situations, and it still requires measurement of CBG, which is not universally available in all laboratory settings. Nevertheless, it represents an important tool in the effort to move cortisol assessment beyond total cortisol alone.
Cortisol Binding Globulin and Estrogen: Key Hormonal Connections
Among the many regulatory inputs that govern CBG levels, cortisol binding globulin estrogen interactions stand out as particularly clinically significant. Estrogen is one of the most potent known stimulators of CBG synthesis, and this relationship has far-reaching implications for how cortisol is distributed in women at various stages of hormonal life.
How Estrogen Upregulates CBG
Estrogen acts on the liver — the primary site of CBG synthesis — to increase transcription of the CBG gene. This is a direct, well-documented effect that can raise plasma CBG concentrations by two- to three-fold under conditions of high estrogen exposure. As the 2012 PMC source confirms, CBG is up-regulated by estrogens and is characteristically high in pregnancy, when circulating estrogen levels are at their physiological peak.
Implications for Pregnant Women
In pregnancy, the rise in CBG driven by placental and ovarian estrogen has two important consequences:
- Total cortisol rises — because more cortisol is bound and therefore not cleared as quickly, raising the total measured pool
- Free cortisol interpretation becomes complex — clinicians must be cautious about interpreting elevated total cortisol as evidence of Cushing's syndrome in pregnant patients without also assessing CBG and free cortisol specifically
The increase in CBG during pregnancy is thought to serve a protective function, buffering the fetus from exposure to maternal glucocorticoids, which can be harmful to fetal development in excessive amounts. This is an elegant example of hormonal crosstalk between reproductive and stress endocrine systems.
Oral Contraceptives and Hormone Replacement Therapy
Women taking estrogen-containing oral contraceptives (OCP) or hormone replacement therapy (HRT) show elevated CBG levels — often significantly so. For clinicians interpreting cortisol tests in women on these medications, this is a critical consideration. A woman on an estrogen-containing OCP may show a total cortisol level that looks elevated or at the high end of normal, yet her free cortisol may be perfectly normal.
Failure to account for the cortisol binding globulin estrogen relationship in these clinical contexts can lead to unnecessary investigation for cortisol excess disorders, representing both a clinical and a health-economic problem.
Menstrual Cycle Variations
Although the estrogen changes across a normal menstrual cycle are smaller than those seen in pregnancy or with OCP use, there is evidence of modest fluctuations in CBG levels across the cycle, peaking around the time of estrogen surging near ovulation. These variations may contribute to the subtle changes in mood, energy, and stress reactivity that some women report at different cycle phases — though this remains an area of active investigation in cortisol CBG research.
CBG and Stress: What Happens During Acute and Chronic Stress
The relationship between CBG and stress is bidirectional, dynamic, and clinically important. Stress — whether acute or chronic — alters the landscape of cortisol transport in ways that affect both the measured values and the biological consequences of cortisol release.
Acute Stress: Rapid Changes in the Free Fraction
During acute psychological or physical stress, the HPA axis is activated within minutes, driving a rapid surge in cortisol secretion from the adrenal cortex. This surge initially increases total cortisol, but CBG can only buffer so much cortisol at once. As CBG binding sites approach saturation, the proportion of free cortisol rises disproportionately — meaning the biological signal delivered to tissues is amplified beyond what the total cortisol increase would suggest.
This nonlinear relationship between total and free cortisol during acute stress is one reason why the 2003 JCEM study — examining patients undergoing the extreme stress of major surgery — specifically recommended accounting for CBG when interpreting total cortisol in acutely stressed or ill patients.
Additionally, during acute inflammation and stress, neutrophil elastase release can cleave CBG at inflammatory sites, locally releasing cortisol precisely where the immune system is active. This targeted delivery mechanism means that CBG and stress physiology are intimately intertwined at the molecular level.
Chronic Stress: Long-Term Regulation of CBG
Chronic stress produces a different picture. Sustained elevation of inflammatory cytokines — which accompanies chronic stress — suppresses hepatic CBG synthesis, gradually lowering plasma CBG levels over time. The consequences include:
- Lower total cortisol readings that may mask normal or elevated free cortisol
- Higher free cortisol bioavailability relative to total cortisol
- Greater tissue glucocorticoid exposure than total cortisol measurements would imply
This has potential relevance for understanding why chronic stress is associated with metabolic syndrome, immune dysregulation, and other glucocorticoid-related complications even in individuals whose total cortisol levels are not dramatically elevated.
CBG in Fatigue, Pain, and Psychiatric Conditions
Emerging research has explored the role of CBG in conditions characterized by abnormal stress responses, including chronic fatigue syndrome (CFS), fibromyalgia, and PTSD. In some studies of these conditions, altered CBG levels have been identified, suggesting that dysregulation of cortisol transport — not just cortisol production itself — may contribute to the disordered stress reactivity seen in these disorders.
This is an area where cortisol CBG research is still developing, and definitive conclusions remain premature. However, the conceptual framework is compelling: if CBG determines how much cortisol reaches tissues, then CBG dysregulation could be a mechanism underlying glucocorticoid-related pathology even in the absence of obvious HPA axis abnormalities.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsCortisol's Biologically Active Form: Why Only Free Cortisol Acts
To truly appreciate the importance of CBG, one must understand what makes free cortisol the cortisol biologically active form while bound cortisol remains inert.
The Steroid Hormone Mechanism of Action
Cortisol belongs to the class of steroid hormones, which exert their effects through intracellular receptors rather than surface membrane receptors. For cortisol to act, it must:
- Cross the cell membrane (steroids are lipid-soluble and can do this)
- Bind to glucocorticoid receptors (GR) in the cytoplasm
- Cause the receptor-cortisol complex to translocate to the nucleus
- Bind to glucocorticoid response elements (GREs) in DNA
- Regulate gene transcription — activating or suppressing hundreds of target genes
The critical first step — crossing the cell membrane — is only possible for cortisol that is free and unbound. When cortisol is bound to CBG, it is too large and polar to diffuse across the lipid bilayer. The CBG-cortisol complex circulates in the bloodstream but cannot enter cells. From a biological action standpoint, it simply does not exist.
This is why the seemingly small free fraction — just 5–10% of total circulating cortisol — carries the entire biological burden. Every gram of glucocorticoid effect — from blood glucose elevation to immune suppression to bone turnover to mood regulation — comes from that small free pool.
Receptor Saturation and Free Cortisol
An important corollary is the concept of glucocorticoid receptor saturation. Glucocorticoid receptors have high but finite affinity for cortisol. Under baseline conditions, free cortisol occupies a portion of available receptors, producing a tonic level of glucocorticoid signaling. During stress, the free fraction rises (both absolutely and as a proportion), receptor occupancy increases, and the glucocorticoid signal amplifies.
This means that relatively modest changes in CBG — and therefore in free cortisol bioavailability — can produce meaningful changes in glucocorticoid signaling, even when total cortisol remains unchanged. Understanding this amplification dynamic is fundamental to modern cortisol CBG research and to interpreting cortisol-related disorders.
Tissue-Level Regulation
It is worth noting that tissues also have mechanisms for locally regulating cortisol activity beyond what plasma free cortisol levels would predict. The enzyme 11β-HSD1 (11-beta-hydroxysteroid dehydrogenase type 1) converts inactive cortisone to active cortisol within cells, amplifying local glucocorticoid action. Conversely, 11β-HSD2 inactivates cortisol to cortisone in tissues like the kidney, protecting mineralocorticoid receptors from inappropriate activation.
These tissue-level mechanisms interact with the systemic regulation governed by CBG, creating a layered system of cortisol control that operates from the whole-body level down to individual cell types.
Cortisol CBG Research: Landmark Studies and 2025 Updates
The body of cortisol CBG research spans multiple decades and scientific disciplines. This section surveys the most important milestones and brings readers up to date with the latest findings.
Foundational Work: 1950s–1980s
As noted, CBG was discovered in the 1950s. Through the subsequent three decades, researchers used increasingly sophisticated biochemical methods to characterize the protein, establishing its molecular weight, carbohydrate composition, primary production site in the liver, and binding constants for cortisol and related steroids. The recognition that CBG belonged to the SERPIN superfamily came as molecular biology matured in the 1980s, revealing unexpected evolutionary connections to proteins involved in coagulation and inflammation.
The Free Cortisol Index Study (2003, JCEM)
As discussed, the 2003 JCEM study examining 31 surgical patients was a clinically defining moment for the field. By demonstrating that the Free Cortisol Index could serve as a practical surrogate for directly measured free cortisol, this research made the concept of accounting for CBG in cortisol interpretation accessible to clinical laboratories without the technical demands of equilibrium dialysis. The study's recommendation that CBG should be measured when interpreting total cortisol in acutely ill patients remains relevant today.
CBG Mutations Research (2012, PMC)
A 2012 review and case-based article published on PubMed Central provided valuable insight into what happens when CBG itself is genetically abnormal. At the time of publication, human CBG mutations were described as rare. One notable case involved the "Santiago" mutation — a genetic variant that resulted in plasma CBG levels approximately 50% of normal. Individuals with this mutation represent a natural experiment: by observing how they respond hormonally, researchers can draw inferences about the functional importance of CBG in cortisol regulation.
The same 2012 source reaffirmed that CBG is produced mainly by the liver, is up-regulated by estrogens, shows elevated levels in pregnancy, and shows reduced levels in cirrhosis — confirming observations that had been building in the literature for decades.
2025 Frontiers in Endocrinology Review
The most current major contribution to cortisol CBG research is the 2025 Frontiers in Endocrinology review titled "Binding for life: corticosteroid binding globulin from vertebrate…" This comprehensive review:
- Confirms CBG's classification as SERPINA6, situating it firmly within the SERPIN superfamily
- Traces the evolutionary conservation of CBG across vertebrate species, suggesting that its function is ancient and biologically fundamental
- Emphasizes that glucocorticoids are normally bound to CBG to limit tissue exposure, reinforcing the protein's role as a hormonal buffer and guardian against excessive glucocorticoid activity
- Reviews current understanding of CBG's role in inflammation-directed cortisol delivery via the neutrophil elastase cleavage mechanism
This 2025 review signals that interest in CBG biology remains vigorous and is expanding from classical endocrinology into evolutionary and comparative physiology — broadening our understanding of why this transport protein exists and what it accomplishes across the animal kingdom.
Free Cortisol, the HPA Axis, and Clinical Implications
The relationship between free cortisol HPA axis function is one of the most clinically critical topics in endocrinology. The HPA axis — comprising the hypothalamus, anterior pituitary, and adrenal cortex — is the central regulatory system for cortisol production, and understanding how free cortisol interfaces with this system is essential for diagnosing and treating adrenal disorders.
How the HPA Axis Regulates Cortisol
The HPA axis operates through a classical negative feedback loop:
- The hypothalamus releases corticotropin-releasing hormone (CRH)
- CRH stimulates the anterior pituitary to release adrenocorticotropic hormone (ACTH)
- ACTH stimulates the adrenal cortex to produce and release cortisol
- Rising cortisol feeds back to the hypothalamus and pituitary, suppressing CRH and ACTH release — completing the feedback loop
Critically, this feedback loop responds to free cortisol, not total cortisol. The glucocorticoid receptors in the hypothalamus and pituitary that sense circulating cortisol and modulate CRH and ACTH are activated only by unbound cortisol. This means that CBG, by modulating the free cortisol fraction, directly influences HPA axis feedback dynamics.
CBG and HPA Axis Sensitivity
When CBG levels are elevated — as in pregnancy or with estrogen therapy — more cortisol is bound and less is free. This reduces the glucocorticoid signal reaching HPA feedback receptors, which can result in a mild disinhibition of ACTH and CRH — meaning the axis becomes slightly more active, producing somewhat more total cortisol to maintain adequate free cortisol feedback. This is part of why pregnant women show elevated total cortisol: the HPA axis compensates for elevated CBG.
Conversely, when CBG is low — as in cirrhosis or critical illness — more free cortisol is available, providing stronger negative feedback to the HPA axis. Total cortisol may appear lower, but free cortisol HPA feedback may be normal or even exaggerated.
Clinical Implications: Adrenal Insufficiency and Cushing's Syndrome
Adrenal insufficiency (AI): In diagnosing AI, clinicians typically use a cortisol stimulation test (Synacthen/ACTH stimulation test) and look for a threshold total cortisol response. But if CBG is low — as it commonly is in critically ill patients — the threshold may need to be adjusted downward because free cortisol will be proportionally higher per unit of total cortisol. Misapplying normal-patient thresholds in critically ill patients with low CBG can lead to missed diagnoses of AI or unnecessary cortisol treatment.
Cushing's syndrome: Excess cortisol production in Cushing's syndrome raises both total and free cortisol. However, because CBG binding is saturable, free cortisol rises disproportionately as total cortisol increases beyond CBG's binding capacity. This is why urinary free cortisol and late-night salivary cortisol — both reflections of free cortisol — are preferred diagnostic markers for Cushing's syndrome over total serum cortisol.
Dynamic testing: Dexamethasone suppression tests assess whether the HPA axis can be suppressed by exogenous glucocorticoid. Again, the response reflects changes in free cortisol availability, and CBG variation can affect how total cortisol changes in response to dexamethasone, particularly in populations with altered CBG levels.
CBG Gene Mutations and What They Reveal
Among the most informative chapters in cortisol CBG research involves individuals who carry mutations in the gene encoding CBG — the SERPINA6 gene. These cases provide unique windows into the physiological consequences of altered cortisol transport.
Rarity of CBG Mutations
As the 2012 PMC review noted, human CBG mutations were rare at the time of publication. This rarity reflects both the evolutionary conservation of CBG (suggesting strong selective pressure to maintain its function) and the possibility that severe mutations are incompatible with normal development, leaving only partial-function variants to be observed clinically.
The Santiago Mutation
One of the most well-characterized CBG variants is the "Santiago" mutation, described in the 2012 PMC case review. Individuals carrying this mutation have plasma CBG levels at approximately 50% of normal — a substantial reduction that provides a natural model for studying the consequences of CBG deficiency.
What do carriers of the Santiago mutation experience? The clinical picture is more subtle than one might expect, which itself is informative. Many carriers do not have overtly abnormal adrenal function, suggesting that the HPA axis can compensate for reduced CBG through the mechanisms described above — producing somewhat more cortisol to maintain adequate free cortisol levels. However, some carriers report chronic fatigue, hypotension, and reduced stress tolerance, consistent with relative glucocorticoid deficiency under challenging conditions.
Implications for Cortisol Testing
Individuals with CBG mutations who present to clinicians can be profoundly misdiagnosed using standard total cortisol measurements. A carrier of the Santiago mutation, with CBG at 50% of normal, might show total cortisol levels consistent with adrenal insufficiency — yet have entirely normal free cortisol and normal adrenal function. Pursuing aggressive investigation for AI in these individuals, or prescribing glucocorticoid replacement, could be both unnecessary and harmful.
This underscores the importance of functional CBG assessment in clinical practice and reinforces the message from cortisol CBG research: binding protein status must be considered alongside absolute cortisol concentrations.
Future Directions
As genetic testing becomes more accessible and whole-exome and genome sequencing more routine, previously unidentified CBG variants are likely to be discovered with greater frequency. Understanding the clinical significance of these variants — whether they predispose individuals to adrenal disorders, metabolic disease, stress intolerance, or other conditions — is an emerging priority in the field.
When Should Clinicians Measure CBG?
Given everything discussed above, a practical question emerges: in what clinical circumstances should healthcare providers actually measure CBG, rather than relying solely on total cortisol?
Situations Where CBG Measurement Adds Clinical Value
1. Critically ill patients: CBG levels fall significantly during critical illness due to reduced synthesis and increased cleavage. Total cortisol thresholds used for diagnosing adrenal insufficiency in the general population may not apply. Measuring CBG (or using salivary/free cortisol where available) provides a more accurate picture of adrenal function.
2. Pregnant women: Dramatically elevated CBG during pregnancy means total cortisol is a poor marker of actual free cortisol bioavailability. Any investigation for cortisol excess or deficiency during pregnancy should account for CBG levels.
3. Women on estrogen-containing contraceptives or HRT: Estrogen elevates CBG, raising total cortisol. Clinicians should not interpret this elevation as evidence of cortisol excess without assessing CBG.
4. Liver disease: Reduced hepatic CBG synthesis lowers total cortisol artificially. Adrenal function testing in cirrhotic or hepatically impaired patients should account for low CBG.
5. Suspected CBG gene mutations: Patients with chronic fatigue, unexplained hypotension, or unexpectedly low total cortisol in the absence of other adrenal pathology may benefit from CBG measurement and genetic testing for SERPINA6 variants.
6. Monitoring cortisol during major surgery or acute illness: As the 2003 JCEM study specifically recommended, CBG should be measured alongside total cortisol in acutely stressed or surgical patients where the Free Cortisol Index is being used to guide clinical decisions.
Practical Limitations
It is important to acknowledge that routine CBG measurement is not yet standard practice in most clinical settings. Reference ranges may vary between laboratories, assay standardization is not universal, and clinical guidelines have not yet been uniformly updated to mandate CBG measurement in the above scenarios. Nevertheless, the evidence base from cortisol transport protein research consistently supports a more nuanced approach to cortisol assessment than total cortisol alone provides.
Frequently Asked Questions
What is cortisol-binding globulin (CBG)?
CBG is a plasma glycoprotein produced primarily by the liver that serves as the main transport protein for cortisol in the bloodstream. It belongs to the SERPIN family (specifically SERPINA6) and was first discovered in the 1950s. By binding the majority of circulating cortisol, CBG regulates how much free, biologically active cortisol is available to tissues at any given time.
How much cortisol is bound vs free in blood?
Approximately 80–90% of circulating cortisol is bound to CBG, with an additional 5–10% loosely bound to albumin. Only the remaining 5–10% circulates as free, unbound cortisol. This small free fraction represents the biologically active pool — the only cortisol that can enter cells, bind to receptors, and produce physiological effects.
Why does CBG affect total cortisol lab results?
Because standard laboratory cortisol tests measure total cortisol — the sum of CBG-bound, albumin-bound, and free cortisol — any change in CBG levels will affect the total cortisol reading even if true free cortisol (and therefore adrenal function) is unchanged. Elevated CBG raises total cortisol; reduced CBG lowers it. This is why conditions that alter CBG, such as pregnancy, liver disease, estrogen therapy, or critical illness, can produce misleading total cortisol results.
When should clinicians measure free cortisol instead of total cortisol?
Free cortisol measurement is particularly important in: critically ill patients with low CBG; pregnant women with elevated CBG; patients on estrogen-containing medications; those with liver disease; and individuals suspected of having CBG gene mutations. Salivary cortisol, urinary free cortisol, and the Free Cortisol Index are practical alternatives when direct free plasma cortisol measurement is unavailable.
What is the Free Cortisol Index (FCI)?
The FCI is a calculated ratio of total serum cortisol to plasma CBG concentration. It was proposed in a 2003 JCEM study of surgical patients as a practical surrogate for directly measured free cortisol, correcting for the confounding effect of CBG variation on total cortisol readings. While not perfect, it provides clinically useful information when direct free cortisol measurement is impractical.
How do pregnancy, estrogen therapy, or liver disease change CBG?
Pregnancy and estrogen therapy dramatically increase CBG levels — sometimes doubling or tripling plasma concentrations — because estrogen stimulates hepatic CBG synthesis. This raises total cortisol artificially. Liver disease (cirrhosis, hepatic failure) reduces CBG production, lowering total cortisol artificially. In both cases, interpreting total cortisol without knowing CBG levels can be deeply misleading.
Are CBG levels useful as a clinical biomarker?
Increasingly, yes — though CBG is not yet routinely measured in standard clinical practice. In research and specialized clinical settings, CBG measurement adds important context to cortisol interpretation and can help identify individuals at risk for misdiagnosis of adrenal disorders. Future clinical guidelines may formalize CBG measurement recommendations for specific patient populations.
What do CBG gene mutations mean for cortisol transport?
CBG gene (SERPINA6) mutations reduce the amount or function of CBG in plasma, meaning less cortisol is bound and total cortisol readings appear lower. The "Santiago" mutation, described in 2012, reduces plasma CBG to approximately 50% of normal. Carriers may have near-normal free cortisol due to HPA axis compensation but can present with symptoms of relative glucocorticoid deficiency under stress and may be misdiagnosed with adrenal insufficiency if only total cortisol is measured.
How is CBG involved in stress, fatigue, and chronic pain?
During acute stress, CBG binding sites approach saturation, amplifying the free cortisol response. During chronic stress or inflammation, CBG levels fall, increasing free cortisol bioavailability per unit of total cortisol. In conditions like chronic fatigue syndrome and fibromyalgia, altered CBG levels have been observed in some studies, suggesting that dysregulated cortisol transport may contribute to abnormal stress responses in these disorders — though definitive conclusions await further research.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsConclusion
The science of cortisol transport is both deeper and more clinically consequential than many appreciate. At the center of it all is cortisol-binding globulin — a protein that has been silently governing glucocorticoid biology since before its discovery in the 1950s and whose importance to clinical medicine continues to grow with each passing decade of research.
The key insights from this comprehensive review of cortisol and cortisol binding globulin research can be distilled into several core principles:
First, approximately 80–90% of circulating cortisol is CBG-bound and biologically inert. Only the free fraction — just 5–10% of total cortisol — represents the cortisol biologically active form capable of entering cells and driving physiological effects.
Second, total cortisol measurements are profoundly affected by CBG levels. Pregnancy, estrogen therapy, liver disease, critical illness, and genetic CBG mutations all change CBG concentrations, distorting total cortisol readings in ways that can lead to diagnostic error if unrecognized.
Third, free cortisol bioavailability — not total cortisol — is what drives HPA axis feedback, tissue glucocorticoid effects, and clinical disease. The free cortisol HPA axis relationship is the functional reality that should guide clinical decision-making.
Fourth, the field of cortisol CBG research continues to advance, with the 2025 Frontiers in Endocrinology review providing the most comprehensive and current synthesis of CBG's biology, evolutionary significance, and clinical relevance. CBG's classification as SERPINA6 and its role in temperature-sensitive, inflammation-directed cortisol delivery represent important modern insights.
Fifth, practical tools — including the Free Cortisol Index, salivary cortisol, and urinary free cortisol — allow clinicians to move beyond total cortisol measurements in situations where CBG variation is likely to be confounding.
For patients, understanding that a cortisol blood test measures mostly inactive, bound hormone can be genuinely illuminating — helping explain why symptoms do not always match total cortisol numbers. For clinicians, integrating CBG assessment into cortisol interpretation is a move toward more precise, individualized endocrine medicine.
The protein that silently carries most of our cortisol through the bloodstream is not silent at all. It is one of the most eloquent storytellers in the language of hormonal regulation — and learning to read what it says transforms how we understand stress, metabolism, immunity, and the remarkable complexity of human physiology.
This article is intended for educational purposes and reflects current scientific research as of 2025. It does not constitute medical advice. Individuals with concerns about cortisol, adrenal function, or related conditions should consult a qualified healthcare provider.
References:
- Frontiers in Endocrinology (2025). "Binding for life: corticosteroid binding globulin from vertebrate…" Frontiers in Endocrinology. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1647096/full
- Health Matters. "Cortisol Binding Globulin (CBG)." https://healthmatters.io/understand-blood-test-results/cortisol-binding-globulin-cbg
- Pugeat M, et al. (2003). "Free cortisol index and the free cortisol index." Journal of Clinical Endocrinology & Metabolism.
- PubMed Central (2012). Case review of CBG mutations and cortisol transport. https://pmc.ncbi.nlm.nih.gov/articles/PMC3251931/
0 comments